Results 121 to 130 of about 31,475 (230)

Antipsychotic Drug Interactions and Short‐Term Mortality Risk in People With Dementia: A National Cohort Study

Clinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 1081-1091, October 2026.
Antipsychotics are often prescribed in the management of behaviors and psychological symptoms of dementia. While the potential harms of antipsychotic use in people with dementia have been established, little is known about the risk associated with antipsychotic drug–drug interactions (DDIs). This study aims to examine the patterns of antipsychotic DDIs
Edward C.Y. Lau, Grace H. Shim, Chin Hang Yiu, Sarah N. Hilmer, Yun‐Hee Jeon, Weisi Chen, Christine Y. Lu, Edwin C.K. Tan   +7 more
wiley   +1 more source

Agomelatine as augmentation therapy with second‐generation antipsychotics for negative symptoms of schizophrenia: An open‐label randomised clinical trial and electroencephalogram‐derived model for treatment response prediction

General Psychiatry, Volume 39, Issue 5, October 2026.
ABSTRACT Background Negative symptoms are a core diagnostic domain of schizophrenia that affect functional outcomes and remain difficult to treat. Agomelatine, a novel antidepressant with melatonin receptor agonism and serotonin 2C receptor antagonism, may have therapeutic potential.
Wanyan Zhou, Fei Liang, Nizhe Chen, Yao Zhang, Xiaoxiao Wang, Xin Li, Daofeng Lu, Fang Guo, Yuan Yao, Jiayu Zhu, Chengjia Shen, Chongze Wang, Peiyun Zhang, Lilan Zhao, Ying Wang, Jinyu Han, Wei Li, Haisu Wu, Peijuan Wang, Qi Yan, Ping Zhang, Qinyu Lv, Zhenghui Yi   +22 more
wiley   +1 more source

A Heterozygous Variant in the GABBR2 Gene in a Girl With Clinical Classic Rett Syndrome

Molecular Genetics &Genomic Medicine, Volume 14, Issue 10, October 2026.
A heterozygous de novo GABBR2 variant was identified in a girl with clinical classical Rett syndrome. Comparison with previously reported cases suggests that GABBR2 variants should be considered in the genetic evaluation of individuals with MECP2‐negative Rett syndrome.
Jenny Klintenstedt, Peter Baeck, Ingegerd Witt Engerström, Cecilia Gunnarsson   +3 more
wiley   +1 more source

Serotonin, sertraline and depression

, 1995
Sertraline is a highly selective serotonin re-uptake inhibitor (SSRI) whose efficacy in depression has been established in a number of large placebo-controlled studies in patients with moderate to severe major depressive episodes (DSM-III).
Stuart Montgomery
core   +1 more source

Updated Estimates of Agreement Between Dispensed Medications and Forensic Toxicology in Sweden

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 10, October 2026.
ABSTRACT Purpose To present updated estimates from a nationwide Swedish study comparing dispensed medications with forensic toxicological findings (2006–2013), following re‐evaluation of the toxicology dataset to address periods with non‐uniform analytical detection and inconsistent testing.
Heidi Taipale, Jari Tiihonen, Antti Tanskanen, Jonas Forsman   +3 more
wiley   +1 more source

Sertraline and inflammatory markers in major depression: a systematic review and meta-analysis

Annals of General Psychiatry
Background Increasing evidence suggests a link between major depressive disorder (MDD) and inflammatory pathways. Sertraline, a commonly used selective serotonin reuptake inhibitor (SSRI), may influence inflammatory cytokine levels.
ZiLiang Xie, Zheng Gao, Xue Li, Shuo Li, Fan Tang, Caiyi Zhang   +5 more
doaj   +1 more source

Concurrent Antidepressant Use and Metastasis Risk Among Women Receiving Tamoxifen for Breast Cancer: A Real‐World Cohort Study

Psycho-Oncology, Volume 35, Issue 10, October 2026.
ABSTRACT Objective Concurrent use of antidepressants, particularly cytochrome P450 2D6 (CYP2D6) inhibitors, may reduce tamoxifen bioactivation and effectiveness. However, the clinical significance of this potential interaction remains inconclusive. This study examined whether concurrent antidepressant use is associated with increased metastasis risk ...
Shaimaa Elshafie, Mohammed Zuber, Ainhoa Gomez‐Lumbreras, Daniel C. Malone, Lorenzo Villa Zapata   +4 more
wiley   +1 more source

Sertraline Hydrochloride [PDF]

, 2017
This poster, presented at the Natural Sciences Poster Session at Parkland College, provides the chemical makeup, dosage, and effects of Sertraline Hydrochloride, trade name Zoloft, used to treat the symptoms of depression, obsessive compulsive disorder ...
Fehr, Michelle L.
core  

Mechanism‐Informed Pharmacotherapy Optimization and Deprescribing: A Redox–Mitochondrial Framework

Pharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.
From cumulative drug burden to mitochondrial stress and functional decline. The graphical abstract summarizes the central concept of the review, illustrating how cumulative pharmacotherapy exposure may contribute to redox–mitochondrial stress and thereby reduce biological and functional resilience.
Boštjan Martinc
wiley   +1 more source

The PREDEP-SERT study protocol: A 6-month follow-up cohort study of predictors of effectiveness, tolerability and safety of sertraline for depression using Therapeutic Drug Monitoring.

PLoS ONE
Sertraline is a common first-line pharmacological treatment of Major Depressive Disorder (MDD). There is no established consensus nor clinical guidelines for personalized dose adjustments, which imply risks of toxicity and lack of efficacy.
Patricio Molero, Covadonga Canga-Espina, Begoña Tapia-Alzuguren, José Pablo Bullard, María Del Mar Unceta-González, Enrique Aubá, Jorge M Núñez-Córdoba, Felipe Ortuño, Azucena Aldaz   +8 more
doaj   +1 more source